Shots:
- Veravas has launched VeraBIND Tau to detect both symptomatic & pre-symptomatic pts with Alzheimer’s disease (AD) or other tau-related neurodegenerative disorders (tauopathies)
- In an analytical verification study, VeraBIND Tau showed 96% sensitivity, 90% specificity, & 92% agreement with tau PET imaging, detecting Alzheimer’s-related tau & offering VeraBIND Tau score, a semi-quantitative measure of pathologically active tau
- VeraBIND Tau is a validated blood-based test that utilizes VeraBIND platform to isolate & measure hyperphosphorylated tau in blood, allowing early identification of Alzheimer’s risk even in cognitively normal individuals
Ref: Prnewswire | Image: Veravas
Related News:- Novocure Reports CE Mark Approval of Optune Lua for Metastatic NSCLC (mNSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
